1 Assistant Professor, University Institute of Pharmaceutical Education & Research, University of Kota, Kota, Rajasthan 324005
2 Assistant Professor, Disha College of Pharmacy, Raipur, Chhattisgarh 492101.
3,4,5,6 University Institute of Pharmaceutical Education & Research, University of Kota, Kota, Rajasthan 324005.
Epigenetic dysregulation, encompassing aberrant DNA methylation, histone modifications, and non-coding RNA expression, is a fundamental driver of oncogenesis and therapeutic resistance. Conventional epigenetic drugs such as DNMT and HDAC inhibitors have demonstrated clinical efficacy, yet their non-specificity, toxicity, and limited bioavailability constrain broader clinical translation. Phytochemicals—bioactive compounds derived from plants—have emerged as potent natural epigenetic modulators capable of reversing malignant gene silencing and restoring normal gene expression. Compounds such as curcumin, resveratrol, quercetin, sulforaphane, and epigallocatechin gallate (EGCG) modulate key epigenetic enzymes and signaling pathways, including DNMTs, HDACs, HMTs, and NF-?B, thereby exerting chemopreventive and anti-cancer effects. In addition, phytochemicals influence non-coding RNAs, modulating oncogenic and tumor-suppressive networks central to cancer progression and inflammation. Despite strong preclinical evidence, their translation remains limited by poor pharmacokinetics, low stability, and variable composition. Recent advances—such as nanoformulation-based delivery, synthetic analog design, and combination therapy with conventional chemotherapeutics—are addressing these challenges. Furthermore, multi-omics integration and AI-driven phytochemical screening are accelerating the discovery of personalized epigenetic interventions. Collectively, phytochemical-based epigenetic modulation offers a promising, non-toxic, and precision-oriented approach to cancer therapy, bridging natural product pharmacology with next-generation epigenetic medicine.
Every community and country is impacted by cancer, which is one of the major causes of mortality globally. The extent to which cancer affects communities and health systems worldwide is referred to as the "global burden of cancer." An estimated 20 million new instances of cancer and 9.7 million cancer-related deaths occurred worldwide in 2022. In most nations, cardiovascular disorders are the major cause of mortality, with cancer coming in second. As populations age and cardiovascular treatments advance, it is predicted to overtake all other causes of mortality in many areas. By 2050, it is anticipated that there will be more than 35 million new instances of cancer. a 77% rise over projections for 2022. Although cancer affects people of all ages, the bulk of instances—64 percent of new cases and 71.3% of deaths in 2020—occur in older persons (60 years of age and older).
1. The role that epigenetics plays in the development of cancer
Epigenetics is the study of heritable variations in gene expression that do not originate from changes in the underlying DNA sequence. The main mechanisms underlying these alterations include chromatin remodeling, histone modifications, DNA methylation, and non-coding RNA control.1 Normal cellular activities and tissue-specific gene expression are preserved in healthy cells by epigenetic processes. When these pathways are disturbed, gene expression may change, which may result in cancer and malignant transformation. Drugs known as epigenetics, which change gene expression without changing DNA sequences, have great potential to treat a number of illnesses, particularly cancer. But there are still a number of significant restrictions that limit their practical usefulness. A large number of epigenetic medications already on the market have a global effect, altering epigenetic markers throughout the genome without regard to cell type or locus specificity. This may result in unexpected alterations in gene expression, which could limit their safe usage due to toxicity and other effects. Natural substances found in plants, including fruits, vegetables, herbs, and grains, are called phytochemicals. Recent studies have demonstrated their strong ability to alter epigenetic mechanisms, which are important processes involved in gene expression and the development of disease. These mechanisms include DNA methylation, histone modification, and microRNA regulation. In clinical settings, off-target effects are a primary contributor to subpar safety and tolerability scores. The potential of negative effects is increased when, for example, widespread suppression of DNA methylation or histone acetylation impacts numerous genes that are not engaged in the disease process Compared to solid tumors, epigenetic medications frequently work better for hematologic malignancies, or blood cancers. This is partially because hematopoietic cells have more cellular plasticity and are more susceptible to epigenetic treatments.2 The limited ability of many epigenetic medications to pass through biological barriers, including the blood-brain barrier, and their poor bioavailability are problems.
There is a chance that aberrant gene expression patterns may reappear after therapy ends since epigenetic changes are reversible by nature. For greater long-lasting effects, combined therapies are required because this frequently leads to illness recurrence. Maintaining a long-lasting pharmacodynamic impact is challenging, particularly when reversible changes necessitate frequent or continuous medication dosage. Cancer Chemoprevention: Because epigenetic modifications are reversible, phytochemicals offer a safer, non-toxic therapeutic approach for targeting early epigenetic changes in carcinogenesis.3
Wide-ranging Effects: The majority of phytochemicals have broad-ranging epigenetic effects, .4 which can be advantageous but also run the danger of non-specific actions akin to those of synthetic epigenetic medications. Delivery and Bioavailability: Phytochemicals frequently struggle with targeted delivery and bioavailability, just like contemporary epigenetic medications. To increase their therapeutic application, innovations like encapsulation.
Limited Clinical Validation: Many phytochemicals have not yet received complete validation in extensive human clinical trials, although showing promise in preclinical research, and their pharmacokinetics need to be optimized.5
2. Epigenetic Mechanisms in Cancer: Role of DNA Methylation & DNMTs
DNA methylation is one of the essential epigenetic processes that controls gene expression without changing the underlying DNA sequence. The formation and spread of cancerous tumors are significantly influenced by aberrant DNA methylation patterns.6
DNA Methylation in Cancer
DNA methylation is the process of attaching a methyl group to a DNA cytosine base, typically at CpG dinucleotides. This process is catalyzed by DNA methyltransferases (DNMTs).
Promoter Hypermethylation: Aberrant methylation, specifically hypermethylation of gene promoter regions, particularly in CpG islands, is frequently observed in cancer cells. Tumor suppressor genes are silenced as a result, which causes unchecked cell survival and proliferation.
Genomic Instability: Methylation in the gene body can result in the synthesis of non-functional proteins, reduce chromosomal stability, and encourage mutations. In cancer cells, promoter methylation that silences DNA repair genes (such MGMT and MLH1) raises the rate of mutations and genomic instability.
Global Hypomethylation: Global DNA hypomethylation is another feature of cancer genomes that can activate oncogenes and lead to tumor heterogeneity and chromosomal instability.
Role of DNMTs
The enzymes known as DNA Methyltransferases (DNMTs), including as DNMT1, DNMT3A, and DNMT3B, are in charge of creating and preserving DNA methylation patterns. Critical genes are silenced and improperly methylated as a result of aberrant DNMT activity in cancer. Therapeutic Target: Drugs intended to block DNMT activity and restore normal gene expression make DNMTs a key target for epigenetic treatment.
Clinical Implications
Diagnostic Biomarkers: Methylation profiles are clinically valuable biomarkers for prognosis, therapy response tracking, and early cancer identification.
Epigenetic Therapy: DNMT inhibitors, including decitabine and azacitidine, can reactivate tumor suppressor genes that have been silenced. They are utilized to treat the hematologic malignancies in particular.
By changing the chromatin structure, histone modifications are essential epigenetic mechanisms that control gene expression. Acetylation and methylation, the two most extensively researched changes linked to gene regulation, are mediated by important enzyme families: histone methyltransferases (HMTs) and histone deacetylases (HDACs).
Histone Deacetylases (HDACs)
Function: Acetyl groups are removed from lysine residues on histone tails by HDACs. Histones and DNA interact more strongly as a result, leading to transcriptional suppression and a more compact (heterochromatic) shape. Hyperacetylation is a characteristic of transcriptionally active chromatin that facilitates transcription factors' access. On the other hand, suppression is associated with hypoacetylation.
Functions in Biology: HDACs play a part in RNA splicing and alternative splicing modulation, chromatin assembly, recombination, chromosomal segregation, and gene transcription. Link between Pathology and Cancers frequently exhibit HDAC overexpression or mutation, which can silence tumor suppressor genes.7
Histone Methyltransferases (HMTs)
Their function is to move methyl groups from S-adenosylmethionine (SAM) to particular histone lysine or arginine sites. In contrast to acetylation, methylation affects the formation of regulatory complexes and protein recruitment (chromatin readers) but does not alter the charge. Arginines can be either mono- or di-methylated, and lysines can be mono-, di-, or tri-methylated. Generally speaking, HMTs target particular residues, such as H3K4, H3K9, and H3K27. H3K9 and H3K27 methylation is linked to gene silence, while H3K4 methylation is linked to active transcription. Methylation marks are involved in the formation, fate determination, and disease states, including cancer, of cells.
Interplay and Therapeutic Implications
Dynamic Modifications: Acetylation and methylation are both reversible and controlled by their respective "erasers" (histone demethylases for methyl marks, and HDACs for acetyl marks). Therapeutic Targeting: HDAC and HMT inhibitors are being developed to awaken dormant tumor suppressor genes and restore normal histone modification patterns in cancer. RNA molecules known as non-coding RNAs (ncRNAs) are essential for controlling gene expression and cellular functions even though they do not code for proteins. Among them, two well-known classes with unique traits and roles are microRNAs (miRNAs) and long non-coding RNAs (lncRNAs).
MicroRNAs (miRNAs)
Size and Structure: Small RNAs with a length of 21–23 nucleotides. Biogenesis Transcribed as primary miRNAs (pri-miRNAs), which are processed into precursor miRNAs (pre-miRNAs), then mature miRNAs Operation primarily use complimentary sequences on target messenger RNAs (mRNAs) to post-transcriptionally control gene expression. This results in translation inhibition or mRNA degradation. Position of the Genome can be transcribed from clusters and is frequently found in intronic or intergenic areas. Biological Functions: impact a variety of activities, including stress reactions, cell division, proliferation, development, and disease pathways, including cancer. Impact of Regulation: play a crucial part in regulating gene expression by modifying between 30–60% of protein-coding genes.
Long Non-coding RNAs (lncRNAs)
Size & Structure: Over 200 nucleotides long; does not encode proteins but is often transcribed like mRNAs. Location present in the cytoplasm and the nucleus. Functions: extremely varied regulatory tasks, such as to change chromatin structure and gene transcription, chromatin-modifying complexes are guided to particular genomic loci. altering the stability and splicing of mRNA. serving as protein complex molecular scaffolds. acting as "sponges" for miRNAs, trapping them to stop target mRNAs from being repressed by miRNAs. Expression varies by developmental stage and illness state and is frequently specific to cell type and tissue. Biological Roles: Essential for differentiation, cell cycle control, development, and disease processes like carcinogenesis. Potential for Therapy: Their stable presence in body fluids and resistance to degradation make lncRNAs promising biomarkers and therapeutic targets.
Interplay Between miRNAs and lncRNAs
By sequestering miRNAs (functioning as "miRNA sponges" or competing endogenous RNAs), lncRNAs can control miRNA activity by modifying the ability of miRNAs to bind their mRNA targets. Certain lncRNAs may function as miRNA precursors. This interaction forms an intricate regulatory network affecting gene expression at multiple levels.8
3. Phytochemicals as Epigenetic Modulators
Natural substances called phytochemicals are present in plants and have the ability to alter gene expression via epigenetic processes. These include impacts on histone modifications, DNA methylation, and the control of non-coding RNAs such microRNAs. Phytochemicals are epigenetic modulators that change chromatin structure and patterns of gene expression by influencing the activity of important enzymes such as DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and histone acetyltransferases (HATs).
Mechanisms of Action:
Histone acetylation and DNA methylation patterns that are frequently disturbed in illnesses like cancer can be restored by phytochemicals that inhibit or regulate DNMTs and HDACs. To increase gene expression, they can change histone modification states and cause tumor suppressor gene promoters to become demethylated. Certain phytochemicals also affect post-transcriptional gene regulation by modifying the expression of microRNA.
Examples of Phytochemicals and Effects Epigallocatechin gallate (EGCG) from green tea suppresses DNMTs and HDACs, which causes promoter demethylation and histone modification to reactivate tumor suppressor genes that have been silenced in a variety of malignancies.
Resveratrol present in berries and grapes, affects HDAC complexes to modify histone acetylation, and affects the activation of tumor suppressor genes.
Curcumin and sulforaphane are additional phytochemicals that have been demonstrated to alter epigenetic enzymes and make cancer cells more susceptible to traditional treatments.
Biological and Therapeutic Implications:
Targeting epigenetic dysregulation, phytochemicals have anti-inflammatory, anti-cancer, and chemopreventive effects. They have the ability to undo abnormal epigenetic modifications linked to inflammation and tumor growth. By epigenetically altering cells, phytochemicals improve the effectiveness of existing treatments.
Epigenetic Modulation in Inflammation:
Through processes related to miRNA, histone changes, and DNA methylation, phytochemicals control the TLR4/NF-κB signaling pathways that are implicated in inflammation. Through epigenetic remodeling, they aid in balancing the expression of genes that promote and inhibit inflammation, which may have implications for the treatment of chronic inflammatory illnesses.
Targeting Histone Modifications
Phytochemicals such as apigenin, quercetin, and sulforaphane are known to affect histone alterations in cancer and other illnesses. These substances alter histone acetylation and methylation, which impacts gene expression and cellular activity.9
Histone Modification Overview
Acetylation and methylation are two examples of histone changes that control chromatin shape and gene accessibility. While methylation can either activate or inhibit gene expression depending on the residue and context, acetylation typically encourages gene activation.10
Sulforaphane: HDAC Inhibitor
As a strong inhibitor of histone deacetylases (HDACs), especially HDAC1 and HDAC3, sulforaphane, which is present in cruciferous vegetables, increases histone acetylation, which relaxes chromatin structure and activates tumor suppressor genes transcriptionally. Sulforaphane can also indirectly affect histone methylation by changing the amounts of methyltransferases and demethylases.11
Quercetin and Apigenin: Broad Modulators
• Flavonoids that regulate histone acetylation and methylation include quercetin, which is present in apples and onions, and apigenin, which is present in parsley and chamomile.
• Quercetin affects histone methyltransferases such as EZH2, which changes levels of H3K27me3 and associated repressive marks, particularly in cancer models.
• It has been demonstrated to reduce HDAC activity, leading to increased acetylation of histone H3 and H4, improving expression of tumor-suppressive genes.
• Apigenin is well known for downregulating methyltransferases like DNMT1 and histone methyltransferases, as well as for decreasing global HDAC expression and activity. These actions promote anticancer gene expression patterns.4
Modulation Mechanisms
Acetylation: These phytochemicals raise histone acetylation by blocking HDACs, which activates genes essential for cell cycle control and tumor suppression.
Methylation: They can change important lysine and arginine methylation marks that affect chromatin state and gene silence by directly or indirectly modifying the activity of methyltransferase and demethylase.
Relevance in Cancer
These dietary interventions are being researched as epigenetic therapeutics in cancer prevention and therapy because of their ability to restore normal acetylation/methylation patterns; they frequently work in conjunction with or as adjuvants to well-known medications.
Targeting Non-Coding RNAs
I discovered pertinent data regarding the epigenetic regulation of inflammation that focuses on non-coding RNAs and the substances withaferin A, berberine, and lycopene. Through pathways involving inhibition of STAT1/3 activation, NF-kappaB, and Akt signaling, withaferin A has been shown to suppress inflammatory responses by downregulating important inflammatory mediators, including cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), and nitric oxide (NO) production in microglial and macrophage cells. Strong anti-inflammatory and immunomodulatory effects are suggested by this.12 Non-coding RNAs (ncRNAs), particularly long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), are important epigenetic regulators in cancer and inflammation. Numerous miRNAs target epigenetic regulators such EZH2, histone deacetylases (HDACs), and DNA methyltransferases (DNMTs) to have oncogenic or tumor-suppressive effects. Both inflammatory and malignant processes are exacerbated by their imbalance. Epigenetic changes such as DNA methylation and histone alterations can also control the production of these miRNAs. By modifying the expression of genes implicated in inflammation and cancer signaling pathways, such as NF-kappaB, berberine partially reduces inflammation and prevents cancer.13 Although precise molecular connections to the epigenetic regulation of non-coding RNAs are less well established, lycopene has shown promise in lowering oxidative stress and inflammation via modifying inflammatory responses. By influencing ncRNA regulation, which governs important inflammatory and carcinogenic pathways, lycopene, berberine, and withaferin A may therefore have anti-inflammatory effects through epigenetic modification. The mechanistic underpinnings of their therapeutic potential may include targeting oncogenic miRNAs and restoring tumor suppressor miRNAs. In the situations of inflammation and cancer, more thorough information on particular miRNAs regulated by these substances and their epigenetic targets can be investigated.
4. Molecular Mechanisms of Action
By directly binding to enzymes, altering important cancer signaling pathways, and affecting the interactions between various epigenetic processes, epigenetic chemicals work through molecular mechanisms.14
Binding to Epigenetic Enzymes
Numerous natural remedies and manufactured epigenetic medications target essential epigenetic enzymes:
DNMTs: Substances such as decitabine and azacytidine bind to DNMTs covalently, causing DNA hypomethylation and the reactivation of tumor suppressor genes that have been silenced.
Histone deacetylases (HDACs): By binding to the HDAC catalytic site, HDAC inhibitors (such as vorinostat and trichostatin A) stimulate gene expression by increasing histone acetylation and relaxing chromatin structure.
Histone methyltransferases (HMTs): Tazemetostat and other small molecule inhibitors of EZH2 prevent methylation of H3K27, which inhibits the growth of cancer cells.
Signal Transduction Pathway Modulation
Signaling pathways are intricately modulated by epigenetic compounds:
PI3K/Akt pathway: HDAC and DNMT inhibitors can block the signals that cancer cells use to survive hypoxia.
MAPK/ERK: By altering upstream kinases, substances like quercetin and sulforaphane affect MAPK signaling, which in turn affects apoptosis and cell cycle progression.
NF-κB: By inhibiting acetylation-dependent transcriptional initiation, epigenetic modulators such as curcumin and withaferin A prevent NF-κB activation, hence lowering inflammation and carcinogenesis.15
Figure 1: Epigenetic Mechanism of phytochemicals.
Crosstalk Between Epigenetic Mechanisms
Complex interactions exist between several epigenetic markers and mechanisms:
Methyl-binding proteins, which interact with HDACs and strengthen gene silencing, can be attracted by DNA methylation. Acetylation and methylation of histones are dynamically related; for instance, methylated DNA areas typically exhibit lower levels of histone acetylation. Non-coding RNAs (miRNAs, lncRNAs) create feedback loops in gene control by controlling the production of epigenetic enzymes and being regulated by epigenetics themselves.
Table 1. Epigenetic targets and biological effects of epigenetic drugs and phytochemicals.
|
Compound |
Pathway/ Target Enzyme |
Molecular Effect |
Biological Result |
|
Azacytidine |
DNMTs |
Demethylation of DNA |
Gene reactivation that has been silenced |
|
Vorinostat |
HDACs |
Hyperacetylation of histones |
Apoptosis, cell cycle arrest |
|
Tazemetostat |
EZH2 (HMT) |
H3K27 methylation inhibition |
Decreased growth of tumors |
|
Quercetin |
NF-κB/MAPK |
Inhibition of signal pathways |
Reduced apoptosis and inflammation |
|
Curcumin |
NF-κB, DNMTs, HDACs |
Multimodal inhibition of enzymes and pathways |
anti-inflammatory and anti-cancer |
5. Preclinical and Clinical Evidence
There is much data supporting epigenetic treatments in both preclinical (in vitro, in vivo) and clinical settings. This is a well-structured summary of the state of the art and key discoveries in each field.16
In Vitro Cell Line Studies
• Human cell line models are widely employed to replicate epigenetic modifications, such as DNA methylation and histone modifications, that occur during carcinogenesis.17
• These models, which replicate the phases seen in clinical disease, aid in the analysis of the gradual transition from normal cells to immortal and malignant phenotypes.
• For determining epigenetic markers and preliminary confirmation of medication effects on epigenetic targets, well-established systems such as the NCI-60 cancer cell line panel, lymphoblastoid cell lines, and immortalized epithelial cell lines continue to be essential.
• To increase translational relevance, future advancements in cell line models include 3D culture and patient-derived iPS cells to replicate tissue microenvironments.1
In Vivo Animal Model Studies
• Epigenetic results and pharmacological responses discovered in vitro are functionally validated using animal models, such as genetically modified mice and xenografts made from human cells.
• These models are essential for preclinical safety and efficacy evaluation before clinical trials, as well as for investigating the biological effects of targeted epigenetic alterations (for example, by DNMT or HDAC inhibitors).4
Clinical Trials (Status, Phase, Outcomes)
A number of epigenetic medications, or "epi-drugs," are presently in clinical testing. Examples include HDAC inhibitors (e.g., vorinostat, romidepsin) and DNA methyltransferase inhibitors (e.g., azacytidine, decitabine).18
While certain epi-drugs are now undergoing clinical research for a variety of diseases and have demonstrated differing degrees of efficacy, others have already received FDA approval for hematological malignancies.
Safety, effectiveness, and biomarker response are tested in completed and ongoing trials (phase 1, 2, and 3). For example, studies using HDAC and DNMT inhibitors in leukemias and lymphomas show single-agent effectiveness, but there is still more research being done on their potential for broader clinical utility (such as in solid tumors).
Tables 2. Evidence tiers supporting epigenetic therapy in cancer.
|
Evidence Type |
Key Features |
Notable Findings |
|
Studies using in vitro cell lines |
Drug mechanism tests and models of epigenetic modifications in carcinogenesis |
Methylation alterations in steps and the epi-drug action test |
|
Animal experiments conducted in vivo |
Confirms effects and toxicity/ safety in entire organisms. |
Safety and effectiveness proof-of-principle for epi-drugs |
|
Clinical studies |
Translational effectiveness: foundation for regulatory approval |
FDA approval for solid tumor trials and some hematological malignancies |
6. Challenges in Translating Phytochemical Epigenetic Therapy
Numerous significant obstacles stand in the way of bringing phytochemical epigenetic treatments from the laboratory to the bedside, such as low stability and bioavailability, challenges with dose optimization, off-target effects, and variations in the natural product composition.19
Low Bioavailability and Stability
The therapeutic efficacy and clinical translation of many promising phytochemicals, including curcumin, sulforaphane, and resveratrol, are severely limited by their low absorption, fast metabolism, and physiological instability. These medicines hardly ever reach high enough concentrations in target tissues to successfully alter cancer epigenetics in the absence of strong molecular delivery systems.
Dose Optimization
The ideal pharmaceutical dosage for successful epigenetic modification frequently varies significantly from dosages employed in animal models or preclinical cell-line research. Establishing safe yet effective regimens in humans is made more difficult by variable metabolism and tissue distribution. For example, genistein exhibits dose-dependent paradoxical effects on DNA methylation or histone modification activities.7
Off-target Effects
Numerous epigenetic and signaling pathways are impacted by phytochemicals, which raises the possibility of unforeseen consequences for the expression of genes in healthy cells. These wide-ranging actions raise safety issues, as off-target modification may interfere with regular cellular processes, necessitating thorough preclinical toxicity evaluations that are frequently absent from early research.20
Variability in Natural Product Composition
Various plant growth, harvesting, and processing techniques can lead to substantial heterogeneity in natural product extracts. Because of this, bioactive phytochemicals' intensity and quantity vary, which makes it difficult to standardize treatment and replicate clinical trial outcomes.21
Additional Considerations
• To selectively increase bioavailability and regulate the metabolic destiny of phytochemicals, advanced delivery systems such nanoparticles are being researched; however, these technologies come with additional complexity and possible regulatory challenges.
• Many epigenetic effects seen in animal models and in vitro are not effectively translated into the clinic due to a lack of large, well-designed clinical trials.
7. Strategies to Overcome Limitations
Advanced medication delivery and combination techniques are major focal points of epigenetic strategies to address limitations in phytochemical epigenetic therapies:
Nanoformulations
To increase the bioavailability, stability, and targeted administration of epigenetic phytochemicals and medications, numerous nanoformulations have been developed, including liposomes, phytosomes, polymeric nanoparticles, solid lipid nanoparticles, and gold nanoparticles. These nanocarriers facilitate sustained release, improve cellular uptake, lessen systemic toxicity, and shield delicate phytochemicals from deterioration. By customizing formulations to patient-specific tumor characteristics, nanoparticle decorating enables precise targeting of tumor cells, enabling individualized treatment.22
Synthetic Analog Development
The pharmacokinetic and pharmacodynamic features of phytochemical analogs or derivatives are optimized through chemical synthesis, which increases stability, potency, and selectivity while lowering off-target effects. This approach produces more drug-like compounds that preserve or improve epigenetic modulation by using natural scaffolds.23
Combination Therapy
There is potential for overcoming resistance mechanisms and improving anticancer efficacy by combining phytochemical epigenetic agents with other anticancer therapies (chemotherapy, immunotherapy) or traditional epigenetic medications (DNMT inhibitors, HDAC inhibitors, etc.). Additionally, by reducing effective doses, these combination techniques assist mitigate dose-limiting toxicities.24
8. Future Perspectives
Here is a thorough investigation based on current research and trends to address future views, such as the function of multi-omics techniques, AI-assisted screening of phytochemical libraries, and individualized epigenetic therapy.25
Role of Multi-Omics Approaches
To provide thorough biological insights, multi-omics combines transcriptomics, proteomics, metabolomics, epigenomics, and genomics. In cancer and other diseases, multi-omics enables:
Improved understanding of disease biology, therapy optimization, and disease phenotype prediction are all made possible by developments in the integration of multi-omics datasets with AI and bioinformatics.26
AI-Assisted Screening of Phytochemical Libraries
The following are some ways that machine learning and artificial intelligence are changing phytochemical research:
• Creating extensive databases of phytochemicals with precise molecular characteristics and anticipated bioactivities.
• Using artificial intelligence (AI)-powered platforms that combine molecular network analysis and drug informatics to speed up virtual screening of phytochemicals against biological targets.
• Accurately predicting the bioactivity and pharmacological characteristics of molecules originating from plants, which aids in drug discovery.
• Artificial intelligence platforms such as HerbIntel automate the screening process for novel drug candidates and predict the drug-like qualities of phytochemicals using machine learning.
• Rapid identification of lead compounds from large phytochemical libraries is made possible by improved AI algorithms, which has particular promise for cancer treatments and epigenetic modulators.27
Personalized Epigenetic Therapy
The goal of personalized epigenetic therapy is to modify phytochemicals or epigenetic medications to fit the unique epigenomic profiles of each patient by:
• Making use of multi-omics profiling to comprehend epigenetic changes unique to each patient (e.g., DNA methylation, histone modifications).
• Creating tailored treatments that alter epigenetic regulators pertinent to the patient's condition. 28
• Using AI to forecast how a patient will react to natural or synthetic epigenetic modulators or medications, increasing therapy effectiveness and lowering adverse effects.
• Using bioinformatics and AI-powered multi-omics data integration to create customized regimens that combine natural and synthetic epigenetic modulators for the best possible results.
This strategy could lead to advances in precision medicine in complicated disorders like cancer, where epigenetic dysregulation is a major factor.29
9. CONCLUSION
As reversible epigenetic mechanisms, such DNA methylation and histone changes, are essential for the genesis and progression of disease, epigenetic therapy has great therapeutic potential. In order to increase their effectiveness and broaden their uses in cancer and other disorders, the FDA has approved a number of epigenetic medications that target enzymes such as DNMTs, HDACs, HMTs, and others. Several clinical trials are also now underway. To improve treatment results and avoid resistance, epigenetic medications show promise when used in conjunction with immunotherapy, targeted therapy, and chemotherapy. Notwithstanding the progress made, additional clinical validation through carefully planned trials is still necessary to completely confirm safety, efficacy, ideal dosage, and biomarker-driven patient stratification techniques. With this kind of confirmation, epigenetic treatments can confidently transition from experimental to clinical settings.30
REFERENCES
Hariom Rajput, Bishesar Sahu, Khushi Rathore, Akshara Khandelwal, Aditya Singh, Aayushi Dadhich, Phytochemicals as Epigenetic Modulators in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 4183-4196. https://doi.org/10.5281/zenodo.20260911
10.5281/zenodo.20260911